PRTG News and Press, Portage Biotech Inc. From 01/04/24

2024-01-04 12:27:00 ET More on Portage Biotech Seeking Alpha’s Quant Rating on Portage Biotech Historical earnings data for Portage Biotech Financial information for Portage Biotech For further details see: Portage Biotech to halt iNKT drug program...

2024-01-04 10:00:14 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Covid-vaccine makers top laggard list, LLY and WST top gainers list Healthcare and uti...

Prioritize the adenosine clinical candidates iNKT clinical development paused to focus resources Company will evaluate range of strategic options WESTPORT, Conn., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-onc...

Portage Biotech Inc. (PRTG) is expected to report $-0.27 for Q2 2024

2023-11-28 16:21:57 ET More on Portage Biotech Portage Biotech stock sheds after announcing $6M registered direct offering Seeking Alpha’s Quant Rating on Portage Biotech Historical earnings data for Portage Biotech Financial information for Portage Bi...

WESTPORT, Conn., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported financial results for the fiscal quarter ended September 30, 2023. ...

Updated data support the proof of concept of using an iNKT engager monotherapy (PORT-2) to induce immune response for patients with non-small cell lung cancer (NSCLC) and melanoma Strong academic interest in the design of the Adenosine 2A(A2A) and Adenosine 2B(A2B) trial for patients wi...

2023-10-31 16:21:05 ET More on Portage Biotech Portage Biotech stock sheds after announcing $6M registered direct offering Seeking Alpha’s Quant Rating on Portage Biotech For further details see: Portage Biotech files to sell 9.63M shares for holders

2023-09-29 09:04:40 ET More on Portage Biotech Seeking Alpha’s Quant Rating on Portage Biotech Historical earnings data for Portage Biotech Financial information for Portage Biotech For further details see: Portage Biotech announces $6M registered ...

WESTPORT, Conn., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that it has entered into a definitive agreement for the purchase ...